Cerebroprotein Hydrolysate

What it is. A mixture of low-molecular-weight peptides and free amino acids produced by enzymatic digestion of purified pig brain protein. Cerebrolysin is the best-known trade name; cerebroprotein hydrolysate is used for equivalent products, and a 2024 comparison examined how the biological activity and composition of Cerebrolysin relate to other peptide preparations [1]. Like Thymalin, it is defined by a process rather than a structure.

Stroke: no benefit, and a harm signal. The Cochrane review has been updated repeatedly since 2010 [4][5][6][7][8], and the 2023 version included seven RCTs with 1773 participants. Moderate-certainty evidence indicates no effect on all-cause death. Serious adverse events showed no difference in the total number of affected people (RR 1.16) or in fatal ones (RR 0.90) - but an increase in non-fatal serious adverse events, RR 2.39 (95% CI 1.10-5.23), rising to RR 2.87 (1.24-6.69) in a subgroup analysis, both at moderate certainty [2]. That is the strongest-certainty finding in the whole review, and it points the wrong way.

Dementia: benefit, at very low certainty. The vascular dementia review found six RCTs with 597 participants. Cognition improved (SMD 0.36, 95% CI 0.13-0.58) and global function improved (RR 2.69, 95% CI 1.82-3.98), with no difference in adverse effects - every one of these graded very low quality, and the authors concluded the evidence base is weak and adequately powered, methodologically robust trials are needed [3][9]. Separate meta-analyses in mild-to-moderate Alzheimer's disease have reported benefit [10][11].

How to read this. The pattern is characteristic: a widely licensed product supported by many small trials from a limited set of countries, which systematically shrink or reverse under Cochrane's methods. The dementia benefit may be real - very low certainty means uncertain, not disproven. But the one thing assessed at moderate certainty in the largest dataset is an increase in non-fatal serious adverse events, and that deserves more weight than a low-certainty cognitive improvement.

The proposed mechanism is neurotrophic: that the low-molecular-weight peptide fraction mimics the action of endogenous neurotrophic factors, supporting neuronal survival, plasticity and repair. Preclinical literature reports effects on neurogenesis, apoptosis and amyloid handling.

The structural problem is the same one that applies to every hydrolysate. There is no defined active molecule, so there is no receptor to characterise, no concentration-response relationship to establish and no way to compare batches or products except by assay. The 2024 comparison of Cerebrolysin's composition and activity against other peptide preparations exists because that question is genuinely open [1].

A further difficulty rarely acknowledged: peptides of the size present in these preparations do not readily cross the blood-brain barrier, and no published work establishes what fraction of an infused dose reaches brain tissue intact.

Supplied as ampoules for intravenous infusion or intramuscular injection. It is a prescription product given in courses, typically over two to three weeks, in the countries where it is licensed - which do not include the United States, the United Kingdom or most of Western Europe.

Equivalence between Cerebrolysin and other cerebroprotein hydrolysate products is assumed in much of the literature rather than demonstrated, which is why the comparison study was undertaken [1].

The clearest finding in the literature is a safety signal, not an efficacy one. In acute ischaemic stroke, moderate-certainty evidence indicates an increase in the total number of people with non-fatal serious adverse events: RR 2.39, 95% CI 1.10-5.23 across three trials and 1335 participants, rising to RR 2.87 (95% CI 1.24-6.69) in a subgroup of two trials and 1189 participants [2]. Fatal serious adverse events did not differ (RR 0.90), nor did the total number of people with any adverse event (RR 1.03, low certainty).

In vascular dementia, adverse effect rates did not differ from control, but only one study contributed and the evidence was very low quality [3].

Two structural concerns follow from what the product is. It is a porcine brain-derived preparation, so sourcing and screening matter in a way they do not for a synthetic peptide. And because composition is set by process, the safety record of one manufacturer's product is not automatically transferable to another's.

No interaction studies have been published. In the stroke trials it was given alongside standard care, so the pooled results describe the addition of cerebroprotein hydrolysate to usual treatment rather than the product alone [2].